ADNOC Gas Targets Up to $4B Profit in 2026 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Airbus Joins Air India A320 Altitude Drop Probe 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
WuXi AppTec (SS:603259), a leading Chinese pharmaceutical services company, announced plans to raise HK$7.70 billion (US$981 million) through a Hong Kong share placement to accelerate its global expansion and boost production capacity.
The company will issue 73.8 million new H-shares priced at HK$104.27 each, representing a 6.9% discount to its July 30 closing price. The placement accounts for approximately 2.51% of WuXi AppTec’s enlarged share capital and will be allocated to at least six institutional investors, according to the company’s statement.
WuXi AppTec stated that net proceeds of around HK$7.65 billion will be used mainly to fund overseas growth, with 90% earmarked for international expansion and capacity building projects. The remaining funds will be allocated for general corporate purposes.
This capital raising comes as WuXi AppTec continues to strengthen its global footprint in contract research, development, and manufacturing services amid rising demand for pharmaceutical outsourcing. The move aligns with the company’s strategy to enhance international operations and meet growing customer needs in key markets such as the United States and Europe.
The placement underscores investor confidence in WuXi AppTec’s growth prospects despite broader market volatility. By securing substantial funding, the company is positioned to expand its global infrastructure and maintain its competitive edge in the fast-evolving life sciences sector.
